Actionable news
0
All posts from Actionable news
Actionable news in ITEK: INOTEK PHARMACEUTICALS CORPORATION COMMON STOCK,

Inotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial of a Fixed-Dose Combination of Trabodenoson, a Novel Treatment for Glaucoma, and Latanoprost

LEXINGTON, Mass--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases, today announced the initiation of a Phase 2 dose-ranging trial of a fixed-dose combination (FDC) of trabodenoson and latanoprost. Glaucoma is one of the leading causes of blindness, and occurs when there is damage to the optic nerve as a result of elevated eye pressure. While the goal of glaucoma treatment is to preserve vision; lowering intraocular pressure (IOP) —a risk-factor for glaucoma—has been shown to prevent progressive vision loss.

“The Phase 2 trial of trabodenoson and latanoprost as a fixed-dose combination in a single eye drop substantially broadens the scope of Inotek’s trabodenoson development program”

Tweet this

Trabodenoson, the Company’s lead clinical candidate, is a first-in-class, highly selective adenosine A1 mimetic which has been observed in Phase 2 clinical trials to reduce IOP. Latanoprost is a prostaglandin analog and the most commonly used drug for lowering IOP. Approximately 50% of glaucoma patients that receive a prostaglandin require a second, adjunctive therapy to achieve sufficient IOP-lowering. However, no combination product with a prostaglandin has been approved in the United States.

“The Phase 2 trial of trabodenoson and latanoprost as a fixed-dose combination in a single eye drop substantially broadens the scope of Inotek’s trabodenoson development program,” said Rudolf Baumgartner, MD, Chief Medical Officer of Inotek. “Trabodenoson is...


More